BackgroundTreatment with anti-EGFR antibody has been shown to prolong survival in patients with RAS wild-type metastatic colorectal cancer (mCRC). However. even patients who initially respond to anti-EGFR antibody therapy. almost without exception. https://oznicoes.shop/product-category/m-bottoms/